| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/11/2006 | US7074409 Polypeptides having a triggering NK activity and biological applications |
| 07/11/2006 | US7074407 immunizing with fragments of CETP (cholesteryl ester transfer protein) which may be conjugated to a carrier, such as KLH (keyhole limpet hemocyanin) or ovalbumin, to increase immunogenicity |
| 07/11/2006 | US7074406 Treating allergic diseases with humanized anti-CD40L antibody |
| 07/11/2006 | US7074405 antibody binds target tissue and conjugate carrying epitope (haptens) |
| 07/11/2006 | US7074404 Protein purification |
| 07/11/2006 | US7074403 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 07/11/2006 | CA2212552C Hepatitis b vaccine |
| 07/11/2006 | CA2117536C Immunological detection of organophosphates |
| 07/11/2006 | CA2078549C Multiple sclerosis t-cell receptor |
| 07/06/2006 | WO2006071983A2 Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| 07/06/2006 | WO2006071949A2 Zebrafish heterotrimer g-protein gamma 2 subunit (gng2) |
| 07/06/2006 | WO2006071940A2 Enzyme modulators and treatments |
| 07/06/2006 | WO2006071896A2 Epitope-based sars vaccine |
| 07/06/2006 | WO2006071877A2 Orally deliverable and anti-toxin antibodies and methods for making and using them |
| 07/06/2006 | WO2006071784A2 Methods for inhibiting melanocyte stem cell loss |
| 07/06/2006 | WO2006071373A1 Stabilization of viral compositions |
| 07/06/2006 | WO2006071280A1 Immunoglobulins comprising predominantly a ga1g1cnacman5glcnac2 glycoform |
| 07/06/2006 | WO2006071206A2 Immunoglobulins whith potent and broad antiviral activity |
| 07/06/2006 | WO2006071091A1 Humanized antibody specific for tumor necrosis factor-alpha |
| 07/06/2006 | WO2006070348A1 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY |
| 07/06/2006 | WO2006070286A2 Monoclonal antibodies against nkg2a |
| 07/06/2006 | WO2006070028A1 Pathogenic infection detection compositions and methods |
| 07/06/2006 | WO2006069505A1 The complex granule of hepatitis b surface antigen containing front surface antigen s1 , s2 and s immune determinants. |
| 07/06/2006 | WO2006059322A3 Implantable device |
| 07/06/2006 | WO2006055024A3 Minicells as vaccines |
| 07/06/2006 | WO2006046963A9 Generation of virus-like particles and use as panfilovirus vaccine |
| 07/06/2006 | WO2006044566A9 Autocrine growth factor receptors and methods |
| 07/06/2006 | WO2006044410A3 A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines |
| 07/06/2006 | WO2006037787A3 Vlp-antigen conjugates and their uses as vaccines |
| 07/06/2006 | WO2006036202A3 Stabilized biodegradable neurotoxin implants |
| 07/06/2006 | WO2006031689A3 Multimeric constructs |
| 07/06/2006 | WO2006017759A3 Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
| 07/06/2006 | WO2006014335A3 Compositions and methods for treatment of non-hodgkin’s lymphoma |
| 07/06/2006 | WO2006004716A3 Amelioration of drug-induced toxicity |
| 07/06/2006 | WO2005118626A3 Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| 07/06/2006 | WO2005116072A3 Antibodies as t cell receptor mimics, methods of production and uses thereof |
| 07/06/2006 | WO2005115451A3 Methods for generating improved immune response |
| 07/06/2006 | WO2005099668B1 Methods of manufacture and use of calcium phosphate particles containing allergens |
| 07/06/2006 | WO2005097993A3 Immunostimulatory viral rna oligonucleotides |
| 07/06/2006 | WO2005076965A3 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
| 07/06/2006 | WO2004084805A3 Acetylated tat polypeptides and methods of use thereof |
| 07/06/2006 | WO2004062603A3 Methods of treating lung diseases |
| 07/06/2006 | WO2004043232A3 Methods for identifying risk of melanoma and treatments thereof |
| 07/06/2006 | WO2003072718A3 In situ induced antigen technology (isiat) for identification of polynucleotides expressed during infection or colonization |
| 07/06/2006 | US20060150264 Differential gene expression in schizophrenia |
| 07/06/2006 | US20060149041 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| 07/06/2006 | US20060149033 IGF antagonist peptides |
| 07/06/2006 | US20060148738 Preventive for adhesion following abdominal surgery |
| 07/06/2006 | US20060148734 Diaminoacid-aminoacid-polyamine based gemini surfactant compounds |
| 07/06/2006 | US20060148709 Neuroprotective properties of GDF-15, a novel member of the TGF-Beta superfamily |
| 07/06/2006 | US20060148694 Inhibition of stress-induced ligand-dependent egfr activation |
| 07/06/2006 | US20060148692 Novel protein and its dna |
| 07/06/2006 | US20060148087 Development of a preventive vaccine for filovirus infection in primates |
| 07/06/2006 | US20060148076 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 07/06/2006 | US20060148055 Oxidised fragments of apolioprotein B and their uses |
| 07/06/2006 | US20060147997 PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases |
| 07/06/2006 | US20060147988 Vertebrate transmembrane protein (UNC-5 protein) for use in diagnosis, prevention and treatment of nervous system disorders |
| 07/06/2006 | US20060147951 "STRAP" and "STEAP" (six transmembrane epithelial antigen of the prostate) |
| 07/06/2006 | US20060147914 evaluating ability of agents to modulate Homer protein activity, Homer protein/immunophilin-peptidylproline cis-trans isomerase interaction, and/or Homer protein/proline-type Homer ligand consensus sequence interaction to identify agents for treatment; modulation of immunosupression and neuroprotection |
| 07/06/2006 | US20060147908 "Prionins", highly specific markers for noninvasive presymptomatic detection of TSE diseases, and targets for therapeutic reagents to prevent and control TSE diseases in animals and humans. |
| 07/06/2006 | US20060147525 Lipophilic drug compositions |
| 07/06/2006 | US20060147509 Composition for vaccination |
| 07/06/2006 | US20060147478 Protein involved in carcinoma |
| 07/06/2006 | US20060147477 Immunogenic compositions |
| 07/06/2006 | US20060147476 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 07/06/2006 | US20060147475 Ringworm vaccine |
| 07/06/2006 | US20060147474 Detection of antibodies against chamydia trachomatis PGP3 antigen in patient sera by enzyme-linked immunoassay |
| 07/06/2006 | US20060147473 Mycobacterium cell wall composition |
| 07/06/2006 | US20060147471 Compositions, methods and devices for preparing less painful Botulinum toxin formulations |
| 07/06/2006 | US20060147470 Cross-protective epitopes of moraxella catarrhalis and use thereof |
| 07/06/2006 | US20060147469 Recombinant hepatitis a virus antigens obtained in plant cells |
| 07/06/2006 | US20060147468 Inactivated influenza virus vaccine for nasal or oral application |
| 07/06/2006 | US20060147467 Materials and methods for immunizing against FIV infection |
| 07/06/2006 | US20060147466 Mucosal combination vaccines for bacterial meningitis |
| 07/06/2006 | US20060147465 Methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides (ORN) in bacteria |
| 07/06/2006 | US20060147464 immunogens; immunololgy; for production of vaccines; able to induce antiserum having neutralizing antibody; neutralization assay; Mareks Disease virus, infectious bronchitis virus, Newcastle disease virus, egg drop syndrome virus, turkey rhinotracheitis virus, or reovirus |
| 07/06/2006 | US20060147463 HSP20 inhibits amyloidogenesis and neurotoxicity |
| 07/06/2006 | US20060147462 For diagnostic, prophylactic and therapeutic uses, vaccines against bacterial infections |
| 07/06/2006 | US20060147461 Use of ClyA hemolysin for excretion of proteins |
| 07/06/2006 | US20060147460 vaccinating a patient against a malignancy by introducing a protein or peptide comprising all or an immunogenic fragment of a cyclin protein into the patient |
| 07/06/2006 | US20060147459 Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| 07/06/2006 | US20060147458 Vaccines |
| 07/06/2006 | US20060147457 Purified composition of bispecific molecules and methods of production |
| 07/06/2006 | US20060147456 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 07/06/2006 | US20060147455 Gastric and colon cancer-associated antigens |
| 07/06/2006 | US20060147454 Human serine protease and serpin polypeptides |
| 07/06/2006 | US20060147453 WISP antagonists such as anti-WISP antibodies for treating cancer; WISP is oncogenic; WISP-1 (Wnt-1 induced secreted protein 1); pancreatic adenocarcinoma, colonic adenocarcinoma, inhibiting lung cancer metastasis |
| 07/06/2006 | US20060147452 Antibody variable region of a monoclonal antibody against human tumor necrosis factor alpha and a gene encoding the same |
| 07/06/2006 | US20060147451 Modulators of hepatocyte growth factor activator |
| 07/06/2006 | US20060147450 Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| 07/06/2006 | US20060147449 Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| 07/06/2006 | US20060147448 Treatment of immunological renal disorders by lymphotoxin pathway inhibitors |
| 07/06/2006 | US20060147447 Secreted peptides |
| 07/06/2006 | US20060147446 Humanized antibodies to human GP39, compositions, and therapeutic uses thereof |
| 07/06/2006 | US20060147445 Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| 07/06/2006 | US20060147444 Biosynthetic binding proteins for immuno-targeting |
| 07/06/2006 | US20060147428 Allogeneic and xenogeneic transplantation |
| 07/06/2006 | US20060147419 Recombinant vaccine viruses expressing il-15 and methods of using the same |
| 07/06/2006 | US20060147418 Recombinant double stranded rna phages and uses thereof |
| 07/06/2006 | US20060147417 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |